{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:06:22Z","timestamp":1789535182967,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR302215"],"award-info":[{"award-number":["NIHR302215"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Naltrexone is a pharmacotherapeutic option for relapse prevention in opioid use disorder (OUD); however, studies highlight low rates of initiation and high rates of discontinuation as limiting its effectiveness. We aimed to (1) estimate the percentage of individuals with OUD who (having undergone withdrawal and wish to remain abstinent) initiate and discontinue naltrexone and (2) examine participant\u2010 and study\u2010level factors that contribute to variation in initiation and discontinuation rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We undertook a systematic review, random\u2010effects meta\u2010analysis and meta\u2010regression searching Medline, Embase, PsychINFO and CENTRAL from database inception to 19 February 2025 for studies of any design from any geographical region involving individuals with OUD eligible to receive naltrexone as a relapse prevention pharmacotherapy (i.e. those completing opioid withdrawal and wishing to remain abstinent). Measurements included the percentage of individuals who initiate or discontinue oral, long\u2010acting injectable depot or implantable formulations of naltrexone at 1, 3 or 6 months. Certainty was assessed using the GRADE framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty\u2010two studies, including 124\u2009016 individuals, reported initiation and 95 studies, including 16\u2009969 individuals, reported discontinuation. The pooled percentage initiating oral naltrexone among those eligible was 60.3% [95% confidence interval (CI) = 38.9%\u201380.0%, 2014 participants, 15 studies] and depot was 18.2% (95% CI = 2.7%\u201342.5%, 57\u2009383 participants, 4 studies). The pooled percentage discontinuing oral was 50.0% (95% CI = 41.9%\u201358.1%, 7340 participants, 34 studies) at 1 month, 61.3% (95% CI = 50.9%\u201371.2%, 2347 participants, 29 studies) at 3 months and 71.0% (95% CI = 57.3%\u201383.0%, 1889 participants, 19 studies) at 6 months. The pooled percentage discontinuing depot was 26.1% (95% CI = 19.5%\u201333.3%, 3589 participants, 33 studies) at 1 month, 46.7% (95% CI = 38.4%\u201355.1%, 3302 participants, 33 studies) at 3 months and 60.0% (95% CI = 43.2%\u201375.8%, 3071 participants, 22 studies) at 6 months. Statistically significantly higher percentages initiated oral naltrexone if it was the only offered pharmacotherapy (meta\u2010regression coefficient 33.6%, 95% CI\u2009= 8.1%\u201359.2%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.014) and statistically significantly lower percentages discontinued oral naltrexone at 3 and 6 months if administration was supervised (meta\u2010regression coefficient \u221218.6%, 95% CI = \u221236.6% to \u22121.0%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.043 and \u221227.3%, 95% CI = \u221250.1% to \u22124.4%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.022, respectively). There was no clear evidence that study setting (i.e. if the study was conducted in routine clinical care or an investigational setting) substantially explained or contributed to the variation in any estimates. All outcomes were very low certainty.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Very low certainty evidence suggests that, among people with opioid use disorder who have undergone withdrawal and wish to remain abstinent, a substantial percentage are willing to initiate naltrexone with marked early discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.70502","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T03:39:51Z","timestamp":1781321991000},"page":"2620-2632","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta\u2010analysis and meta\u2010regression"],"prefix":"10.1111","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4152-5570","authenticated-orcid":false,"given":"Emmert","family":"Roberts","sequence":"first","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London  London UK"},{"name":"National Drug and Alcohol Research Centre University of New South Wales  Sydney Australia"},{"name":"South London and the Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sanderson","sequence":"additional","affiliation":[{"name":"South London and the Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1218-3946","authenticated-orcid":false,"suffix":"Jr.","given":"Thomas","family":"Santo","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-459X","authenticated-orcid":false,"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[{"name":"University of Bristol  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7008-8130","authenticated-orcid":false,"given":"Michael","family":"Farrell","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8513-2218","authenticated-orcid":false,"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1081\/ja-120002807"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00095-0"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14188"},{"issue":"3","key":"e_1_2_9_5_1","first-page":"231","article-title":"Characteristics of individuals seeking to transition from BUP to XR\u2010NTX in a randomized, placebo\u2010controlled trial","volume":"29","author":"Douaihy A","year":"2020","journal-title":"Am J Addict"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14180"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14946"},{"key":"e_1_2_9_8_1","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"2","author":"Minozzi S","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1003257"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.17545"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595230412331289464"},{"key":"e_1_2_9_12_1","volume-title":"NSW clinical guidelines: treatment of opioid dependence\u20142018","author":"Health NMo","year":"2018"},{"key":"e_1_2_9_13_1","unstructured":"StrangJ Group IEW.Drug misuse and dependence: UK guidelines on clinical management.2017."},{"key":"e_1_2_9_14_1","unstructured":"AlderksCE.Trends in the use of methadone buprenorphine and extended\u2010release naltrexone at substance abuse treatment facilities: 2003\u20132015 (update).2017."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952998109009554"},{"issue":"19","key":"e_1_2_9_16_1","first-page":"321","article-title":"Naltrexone in the treatment of opiate dependence","author":"Resnick RB","year":"1978","journal-title":"NIDA Res Monogr"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-022-00317-2"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108183"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00654.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000302"},{"key":"e_1_2_9_23_1","unstructured":"GRADE.http:\/\/www.gradeworkinggroup.org"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_9_25_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins JPT","year":"2011"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1214\/aoms\/1177729756"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7620860"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00134-0"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.bp.111.035063"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.05.008"},{"issue":"9","key":"e_1_2_9_33_1","first-page":"46","article-title":"Naltrexone treatment for addicted health\u2010care professionals: a collaborative private practice experience","volume":"45","author":"Ling W","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0740-5472(97)00020-2"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000193"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595239800186971"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12095"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60358-9"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32893-3"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70502","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.70502","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:01:07Z","timestamp":1789534867000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.70502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/add.70502"],"URL":"https:\/\/doi.org\/10.1111\/add.70502","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"2025-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}